Management to Host Conference Call at
“The third quarter of 2017 has been a productive one for Aclaris. In August, we closed the acquisition of
Clinical Pipeline Update
- A-101 40% Topical Solution
• In September, published results from a Phase 2 clinical trial evaluating two concentrations (40% and 32.5%) of its drug candidate A-101 for the treatment of facial seborrheic keratosis (SK) lesions in the journal Dermatologic Surgery. In the trial, A-101 achieved statistically significant improvement in clearing SK lesions on the face in a dose-related fashion. A-101 was well tolerated at both concentrations studied.
• The FDA’s Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) is
December 24, 2017. If approved, A-101 40% Topical Solution would be the first FDA-approved medication for SK.
- A-101 45% Topical Solution
• In June, initiated two Phase 2 clinical trials of A-101 45% Topical Solution (A-101 45%) for the treatment of common warts. The Phase 2 clinical trials are designed to evaluate the safety, tolerability and dose frequency of A-101 45% compared with placebo in adult and pediatric patients.
• Enrollment in both phase 2 trials has been completed and 316 patients have been enrolled in the two double-blinded trials which are being conducted at 34 investigational centers within
the United States. Aclaris expects to report data from these two trials in the first half of 2018.
- JAK Inhibitors
• In October, initiated a Phase 2 clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) for the treatment of alopecia areata (AA). This trial will evaluate the pharmacokinetics, pharmacodynamics and safety of ATI-50002 Topical compared with placebo in 12 patients with AA. This randomized, double-blind clinical trial is being conducted at two investigational centers within
the United States, and data is expected to be available in the first half of 2018.
• In November, initiated a Phase 2 open-label clinical trial of ATI-50002 Topical for the treatment of AA. This trial will evaluate the effect of ATI-50002 Topical on the regrowth of eyebrows in up to 24 patients with AA. This trial is being conducted at two investigational centers in
Sydneyand Melbourne, Australia, and data is also expected to be available in the first half of 2018.
• Continue plans to initiate a Phase 2 dose ranging trial of ATI-50002 Topical for the treatment of AA next week. This study is a randomized, double-blinded, parallel-group, vehicle controlled trial and plan to enroll approximately 120 patients at 20 investigational centers within
the United States. Data is expected to be available by year end 2018.
• Continue plans to initiate a Phase 2 open-label clinical trial of ATI-50002 Topical for the treatment of vitiligo by the end of 2017.
• Now plan to initiate a Phase 2 dose ranging trial of ATI-50001, an oral JAK inhibitor, for the treatment of AA in the first half of 2018.
• Continue to develop another series of topical JAK inhibitors for the treatment of androgenetic alopecia (AGA).
Business Highlights and Recent Developments
- In August, completed the acquisition of Confluence, a privately held biotechnology company focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
- In August, raised net proceeds of
$80.9 millionfrom a follow-on offering of our common stock.
- In September, the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 9,737,469 and U.S. Patent No. 9,730,877, and the Japan Patent Office issued Japanese Letters Patent No. 6212107. These patents are directed to methods related to the use and administration of certain JAK inhibitors for treating hair loss disorders. These newly issued patents are owned by The Trustees of
Columbia Universityin the City of New Yorkand exclusively licensed to Aclaris.
• U.S. Patent No. 9,730,877 covers the use of various JAK inhibitors, including tofacitinib, baricitinib, ruxolitinib and decernotinib, to treat AGA, also known as male/female pattern hair loss. The ‘877 Patent contains 22 claims and expires in
• U.S. Patent No. 9,737,469 covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as AA and AGA. Additional issued claims pertain to methods of using baricitinib to treat particular phenotypes of AA, as well as to treat other hair loss disorders. The ‘469 Patent contains 10 claims and expires in
• Japanese Letters Patent No. 6212107 covers the use of tofacitinib in a topical composition or as the sole active therapeutic agent in a pharmaceutical composition for inducing hair growth and for treating hair loss disorders, such as AA and AGA. The ‘107 patent issued with 25 claims and expires in
- In October,
Columbia Universityreceived a Notice of Allowance from the USPTO for a patent application covering methods of treating a hair-loss disorder, such as AA and AGA, or inducing hair growth, by administering tofacitinib topically or by administering tofacitinib as the sole active ingredient, and treating AGA or inducing hair growth in a subject having AGA by administering tofacitinib. The application was allowed with 66 claims.
- In October, hosted inaugural R&D and Investor Day event.
Liquidity and Capital Resources
- As of
September 30, 2017, Aclaris had aggregate cash, cash equivalents and marketable securities of $227.8 millioncompared to $174.1 millionas of December 31, 2016. The $53.7 millionincrease during the nine months ended September 30, 2017included:
• Aggregate net proceeds of
$100.2 millionfrom the public offering of common stock in August 2017and the sale of common stock under an at-the-market facility with Cowen in May 2017.
$9.6 millionof cash used to acquire Confluence, net of cash acquired.
• Net loss of
$45.6 millionand $1.2 millionof net cash used in working capital, partially offset by $10.4 millionof non-cash stock-based compensation expense, depreciation and amortization.
- Aclaris anticipates that its cash, cash equivalents and marketable securities as of
September 30, 2017will be sufficient to fund its operations into the second half of 2019, without giving effect to any potential new business development transactions or financing activities.
Third Quarter 2017 Financial Results
- Net loss was
$18.2 millionfor the third quarter of 2017, compared to $10.7 millionfor the third quarter of 2016.
- Revenue of
$0.7 millionand cost of revenue of $0.5 millionfor the third quarter of 2017 related to Confluence’s contract research organization (CRO) business acquired in August 2017.
- Total operating expenses for the third quarter of 2017 were
$19.0 million, compared to $10.8 millionfor the third quarter of 2016.
• Research and development expenses were
$10.9 millionfor the third quarter of 2017, compared to $7.2 millionfor the third quarter of 2016. The increase of $3.7 millionwas primarily attributable to a $1.2 millionincrease in expenses related to the Phase 2 clinical trials of A-101 45%, a $1.3 millionincrease in personnel-related expenses, including stock-based compensation, due to increased headcount, a $0.9 millionincrease in preclinical and clinical trial development expenses related to the JAK inhibitor technology and a $0.9 millionincrease in medical affairs expenses and other costs, including early stage drug discovery, offset in part by a $1.2 milliondecrease in clinical costs for A-101 40% Topical Solution resulting from the completion of Phase 3 clinical trials in November 2016.
• General and administrative expenses were
$8.1 millionfor the third quarter of 2017, compared to $3.7 millionfor the third quarter of 2016. The increase of $4.4 millionwas primarily attributable to $1.9 millionin higher personnel-related expenses, including stock-based compensation, due to increased headcount, and $0.4 millionin expenses related to the acquisition of Confluence. Additionally, Aclaris had a $1.6 millionincrease in market research and sales operations expenses related to pre-commercial activities for A-101 40% Topical Solution.
- As of
September 30, 2017, Aclaris had approximately 30.8 million shares of common stock outstanding.
2017 Financial Outlook
Aclaris is updating its estimates for the following financial metrics for the full year 2017, which estimates now incorporate the acquisition of Confluence:
- Cash burn for 2017, excluding this year’s financing activities and cash paid in the Confluence acquisition, is now estimated to be in the range of
$56 million to $59 millioncompared to previous guidance of $65 million to $70 million.
- Total operating expenses for 2017 are now estimated to be in the range of
$72 million to $75 million, or $57 million to $60 millionwhen excluding estimated stock-based compensation expense of $15 million. Prior guidance for operating expenses was $84 million to $92 million, or $70 million to $75 millionwhen excluding stock-based compensation of $14 to $17 million.
- Research and development expenses for 2017 are now estimated to be in the range of
$39 million to $42 million, or $33 million to $36 millionwhen excluding estimated stock-based compensation expense of $6 million. Prior guidance for research and development expenses was $51 million to $58 million, or $46 million to $52 millionwhen excluding stock-based compensation of $5 million to $6 million.
Company to Host Conference Call
Management will conduct a conference call at
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 99295180 prior to the start of the call.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ use of cash and its research and development and total operating expenses during 2017 and the clinical development of its product candidates, including the availability of data from its ongoing and planned clinical trials and timing for initiation of planned clinical trials, and its belief that its existing capital resources will be sufficient to fund its operations into the second half of 2019. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended
|Aclaris Therapeutics, Inc.|
|Consolidated Statements of Operations|
|(in thousands, except share and per share data)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Cost of revenue||453||‑||453||‑|
|Research and development (1)||10,864||7,162||26,601||26,533|
|General and administrative (1)||8,123||3,650||20,611||10,407|
|Total operating expenses||18,987||10,812||47,212||36,940|
|Loss from operations||(18,756)||(10,812)||(46,981)||(36,940)|
|Other income, net||564||118||1,392||336|
|Net loss per share, basic and diluted||$||(0.63)||$||(0.50)||$||(1.68)||$||(1.76)|
|Weighted average common shares outstanding, basic and diluted||28,834,808||21,415,871||27,180,244||20,752,590|
|(1) Amounts include stock-based compensation expense as follows:|
|Cost of revenue||$||130||$||‑||$||130||$||‑|
|Research and development||1,332||623||3,853||1,577|
|General and administrative||2,211||995||6,147||2,617|
|Total stock-based compensation expense||$||3,673||$||1,618||$||10,130||$||4,194|
|Aclaris Therapeutics, Inc.|
|Selected Consolidated Balance Sheet Data|
|September 30, 2017||December 31, 2016|
|Cash, cash equivalents and marketable securities||$||227,848||$||174,134|
|Total current liabilities||9,993||6,223|
|Total stockholders' equity||244,259||169,490|
Vice President / Investor Relations
Source: Aclaris Therapeutics, Inc.